Pediatrix reaffirms 2026 Adjusted EBITDA outlook of $280 million to $300 million
Pediatrix Medical Group said in a July 15, 2026 update on its second quarter that its payor mix stayed stable and in line with recent trends and internal expectations, and it has not seen material changes in other net revenue trends. The company reaffirmed its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million, and it did not report second quarter financial results in this filing. Full results are due in a release on August 4, 2026.
Key points
- Full year 2026 Adjusted EBITDA outlook reaffirmed at $280 million to $300 million
- Second quarter payor mix stable and unchanged relative to recent historical trends and internal expectations
- Company says it has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector
- Investor conference call and detailed results release scheduled for August 4, 2026, at 9:00 a.m. ET
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.